Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NICE Decision On Arthritis Opens Door For Biosimilars

UK Recommends Treating Moderate Rheumatoid Arthritis With Three Biologic Molecules

Executive Summary

A decision by the UK’s NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.

You may also be interested in...



Biosimilars Industry Urges Improved UK Evaluation Process

A more efficient system to pave a path to market for biosimilars is needed in the UK, the British Biosimilars Association has urged, as it welcomed recent moves to broaden the use of adalimumab, etanercept and infliximab for treating moderate as well as severe rheumatoid arthritis.

Sandoz’s Saynor Sees Tipping Point For Biosimilars

A combination of factors – including recent moves in the UK to broaden access to biosimilars for rheumatoid arthritis patients, as well as the new MHRA pathway for biosimilars and a growing call for global regulatory alignment – are contributing to a “biosimilar Zeitgeist” that could see long-in-the-making change coming for the industry, according to Sandoz CEO Richard Saynor.

Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing

Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.

Topics

UsernamePublicRestriction

Register

GB151004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;